Celera Genomics Group-an Applera Corp. Business Announces Clinical Milestone Payment from Merck & Co., Inc.
28 Sep 2007
ROCKVILLE, Md. & ALAMEDA, Calif.--(BUSINESS WIRE)--Celera (NYSE:CRA), an Applera Corporation business, today announced a clinical milestone payment of $2 million from Merck & Co., Inc. under the cathepsin K inhibitor collaboration agreement between the companies.
This payment recognizes Merck’s advancement of odanacatib (formerly MK-0822), an orally available highly selective inhibitor of the cathepsin K enzyme, into a Phase III clinical trial as a potential treatment for osteoporosis. If this candidate or others developed under the cathepsin K collaboration are advanced further toward commercialization, Celera will receive additional milestone payments and potentially royalties on net sales from Merck.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.